Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 9/20 | 0.55 |
| ▸ | DRD2 | P14416 | 8/20 | 0.55 |
| ▸ | DRD3 | P35462 | 8/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15779863 | 0.85 | DRD4 (0.53) | DRD4DRD2DRD3MAPTSMN1; SMN2 | |
| SCHEMBL16062853 | 0.83 | RXRA (0.47) | DRD4DRD2DRD3MAPTSMN1; SMN2 | |
| SCHEMBL10235445 | 0.83 | MELK (0.42) | DRD4DRD2DRD3MAPTSMN1; SMN2 | |
| SCHEMBL12369718 | 0.82 | CYP2A6 (0.49) | DRD4DRD2DRD3MAPTSMN1; SMN2 | |
| SCHEMBL9048864 | 0.81 | DRD4 (0.52) | DRD4DRD2DRD3MAPTKDM4E | |
| SCHEMBL1754914 | 0.81 | DRD2 (0.52) | DRD4DRD2DRD3MAPTSMN1; SMN2 | |
| SCHEMBL12235674 | 0.81 | GRM4 (0.49) | DRD4DRD2DRD3MAPTSMN1; SMN2 | |
| SCHEMBL6852145 | 0.81 | DRD4 (0.55) | DRD4DRD2DRD3MAPTSMN1; SMN2 | |
| SCHEMBL2412911 | 0.81 | GAA (0.58) | DRD4DRD2DRD3MAPTSMN1; SMN2 | |
| SCHEMBL2408942 | 0.81 | DRD4 (0.55) | DRD4DRD2DRD3MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154314-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-3452464-B1 | PYRAZOLE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USE THEREOF | HOFFMANN LA ROCHE (CH) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020252229-A2 | INHIBITORS OF SARM1 | DISARM THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| US-10588900-B2 | Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-10568876-B2 | Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 | MERCK SHARP & DOHME CORP. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10206931-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20190046520-A1 | QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2019-02-14 | — | — | US | disclosed |
| WO-2018075842-A1 | CONDENSED BENZODIAZEPINE DERIVATIVES AND CONJUGATES MADE THEREFROM | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-26 | — | — | WO | disclosed |
| WO-2017191098-A1 | PYRAZOLE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-09 | — | — | WO | disclosed |
| US-20170273965-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | MERCK SHARP & DOHME CORP. (US) | 2017-09-28 | — | — | US | disclosed |
| EP-1921077-B1 | AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-07-26 | — | — | EP | disclosed |
| EP-3002283-B1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-06-14 | — | — | EP | disclosed |
| WO-2016055028-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| US-8835470-B2 | Mandelamide heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | MERCK & CO., INC. (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273965-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | DGAT2, DGAT1, MOGAT2 | DRD4 3013/4885DRD2 2017/4885DRD3 2710/4885 |
| US-10568876-B2 | Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 | DGAT2, DGAT1, MOGAT2 | DRD4 3013/4885DRD2 2017/4885DRD3 2710/4885 |
| US-20190046520-A1 | QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | DRD4 4722/4885DRD2 3844/4885DRD3 4400/4885 |
| US-10206931-B2 | Therapeutic compounds and uses thereof | EP300, CREBBP, HDAC1 | DRD4 4845/4885DRD2 4787/4885DRD3 4717/4885 |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | CNR1, CNR2, FAAH | DRD4 2853/4885DRD2 1064/4885DRD3 2078/4885 |
| US-10588900-B2 | Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | DRD4 4722/4885DRD2 3844/4885DRD3 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.